Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, MD PhD, Peter Johnson, MD FRCP, Kim M Linton, MBChB, PhD, Martine E.D. Chamuleau, MD PhD, David John Lewis, MD, Anna Sureda Balari, MD PhD, David Cunningham, MD FRCP, FMedSci, Roberto S Oliveri, MD PhD, Dena DeMarco, Brian Elliott, MD, Kuo-mei Chen, PhD, Pieternella J. Lugtenburg, MD PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-133820

Published: 2020

Journal Articles

Successful Treatment of MYC rearrangement Positive Large B Cell Lymphoma Patients with R-CHOP21 Plus Lenalidomide: Results of a Multicenter Phase II HOVON Trial

Martine E.D. Chamuleau, MD, Marcel Nijland, MD, Josée M Zijlstra, MD, Rogier Mous, MD PhD, P.J. Lugtenburg, Daan Dierickx, MD PhD, Gustaaf van Imhoff, MD PhD, Joost Vermaat, MD PhD, Katerina Bakunina, Erik W.A. Marijt, MD, Otto Visser, MDPhD, Caroline Mandigers, MD, Yavuz Bilgin, MDPhD, Coreline Burggraaff, Otto Hoekstra, MDPhD, Daphne de Jong, Prof Dr, Marie José Kersten, MD

Blood (2018) 132 (Supplement 1): 786.

https://doi.org/10.1182/blood-2018-99-110240

Published: 2018

Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2018-99-114723

Published: 2018

Journal Articles

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Hilma J. Van Der Horst, MSc, Simone C. Oostindie, MSc, Saskia AGM Cillessen, MSc, Anne T Gelderloos, MSc, Marije B Overdijk, Martine E.D. Chamuleau, MD, Esther C. W. Breij, PhD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2018-99-115886

Published: 2018

Journal Articles

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Sara Alonso, MD, Martina Manni, PhD, Clementine Sarkozy, MD, Marielle Wondergem, MD, Attilio Guarini, MD, Laura Magnano, MD, Miguel Alcoceba, PhD, Martine E.D. Chamuleau, MD, Sara Galimberti, Maria Gomes da Silva, MD, Harald Holte, MD PhD, Emanuele Zucca, MD, Silvia Montoto, MD, Sandra Lockmer, MD, Igor Aurer, MD PhD, Luigi Marcheselli, MSc, Dolores Caballero, MD, Gilles Salles, MD PhD, Massimo Federico, MD

Blood (2018) 132 (Supplement 1): 4145.

https://doi.org/10.1182/blood-2018-99-115956

Published: 2018

Journal Articles

Low CLIP Expression On Leukemic Blasts From AML Patients Is Essential for the Generation of Effective CD4 + T Cell Responses.

Marvin M. van Luijn, Martine E.D. Chamuleau, MD, PhD, James A. Thompson, Suzanne Ostrand-Rosenberg, PhD, Theresia M. Westers, PhD, Yuri Souwer, Gert J. Ossenkoppele, MD, PhD, S. Marieke van Ham, PhD, Arjan A. van de Loosdrecht, MD, PhD

Blood (2009) 114 (22): 996.

https://doi.org/10.1182/blood.V114.22.996.996

Published: 2009

Journal Articles

Myeloid Leukemic Blasts Use the Endogenous HLA Class I Antigen Processing Machinery for Peptide Loading Onto HLA Class II Molecules: Implications for Immunotherapy.

Marvin M. van Luijn, Martine E.D. Chamuleau, MD, PhD, Maaike E. Ressing, PhD, Emmanuel J.H.J. Wiertz, PhD, Suzanne Ostrand-Rosenberg, PhD, Yuri Souwer, Adri Zevenbergen, Gert J. Ossenkoppele, MD, PhD, Arjan A. van de Loosdrecht, MD, PhD, S. Marieke van Ham, PhD

Blood (2009) 114 (22): 3114.

https://doi.org/10.1182/blood.V114.22.3114.3114

Published: 2009

Journal Articles

TAP- and Proteasome-Dependent Endogenous Antigen Loading of HLA Class II in Leukemic Blasts Introduces a Promising New Target for Generating Leukemia-Specific CD4 + T Cells

Marvin M. van Luijn, MSc, Maaike E. Ressing, PhD, Emmanuel J.H.J. Wiertz, PhD, Adri Zevenbergen, Martine E.D. Chamuleau, MD, Yuri Souwer, MSc, Suzanne Ostrand-Rosenberg, PhD, Gert J. Ossenkoppele, MD, PhD, Arjan A. van de Loosdrecht, MD, PhD, S. Marieke van Ham, PhD

Blood (2008) 112 (11): 5443.

https://doi.org/10.1182/blood.V112.11.5443.5443

Published: 2008

Journal Articles

Modification of Invariant Chain and CLIP Expression Increases the Immunogenicity of Leukemic Blasts to Potentiate Leukemia-Specific T Cell Reactivity

Marvin M. van Luijn, MSc, Martine E.D. Chamuleau, MD, James A. Thompson, PhD, Suzanne Ostrand-Rosenberg, PhD, Theresia M. Westers, PhD, Yuri Souwer, MSc, Gert J. Ossenkoppele, MD, PhD, S. Marieke van Ham, PhD, Arjan A. van de Loosdrecht, MD, PhD

Blood (2008) 112 (11): 5430.

https://doi.org/10.1182/blood.V112.11.5430.5430

Published: 2008

Journal Articles

T Cell Mediated Autologous Cytotoxicity Against Hematopoietic Precursor Cells in Low and Intermediate-1 Risk Myelodysplastic Syndrome.

Martine E.D. Chamuleau, MD, Theresia M. Westers Ing, Linda van Dreunen, Judith Groenland, Adri Zevenbergen Ing, Corien Eeltink, Gert J. Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2007) 110 (11): 4603.

https://doi.org/10.1182/blood.V110.11.4603.4603

Published: 2007

Journal Articles

High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome.

Martine E.D. Chamuleau, MD, Arjan A. Van de Loosdrecht, MD, PhD, Corine J. Hess, MD, Jeroen J.W.M. Janssen, MD, Adri Zevenbergen, Ruud Delwel, PhD, Peter J.M. Valk, PhD, Bob Lowenberg, MD, PhD, Gert J. Ossenkoppele, MD, PhD

Blood (2007) 110 (11): 4297.

https://doi.org/10.1182/blood.V110.11.4297.4297

Published: 2007

Journal Articles

TRAIL-R3 Expression on Myeloid Leukemic Blasts Is Related to a Shortened Overall Survival.

Martine, E.D. Chamuleau, MD, Adri Zevenbergen, Arjan A. van de Loosrdrecht, MD, PhD, Gert J. Ossenkoppele, MD, PhD

Blood (2005) 106 (11): 2768.

https://doi.org/10.1182/blood.V106.11.2768.2768

Published: 2005

NARROW

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Successful Treatment of MYC rearrangement Positive Large B Cell Lymphoma Patients with R-CHOP21 Plus Lenalidomide: Results of a Multicenter Phase II HOVON Trial

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Low CLIP Expression On Leukemic Blasts From AML Patients Is Essential for the Generation of Effective CD4 + T Cell Responses.

Myeloid Leukemic Blasts Use the Endogenous HLA Class I Antigen Processing Machinery for Peptide Loading Onto HLA Class II Molecules: Implications for Immunotherapy.

TAP- and Proteasome-Dependent Endogenous Antigen Loading of HLA Class II in Leukemic Blasts Introduces a Promising New Target for Generating Leukemia-Specific CD4 + T Cells

Modification of Invariant Chain and CLIP Expression Increases the Immunogenicity of Leukemic Blasts to Potentiate Leukemia-Specific T Cell Reactivity

T Cell Mediated Autologous Cytotoxicity Against Hematopoietic Precursor Cells in Low and Intermediate-1 Risk Myelodysplastic Syndrome.

High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome.

TRAIL-R3 Expression on Myeloid Leukemic Blasts Is Related to a Shortened Overall Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only